دورية أكاديمية
Biological Sample Collection to Advance Research and Treatment: A Fight Osteosarcoma Through European Research and Euro Ewing Consortium Statement.
| العنوان: | Biological Sample Collection to Advance Research and Treatment: A Fight Osteosarcoma Through European Research and Euro Ewing Consortium Statement. |
|---|---|
| المؤلفون: | Green D; Biomedical Research Centre, Norwich Medical School, University of East Anglia, Norwich, United Kingdom., van Ewijk R; Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands., Tirtei E; Pediatric Oncology, Regina Margherita Children's Hospital, Turin, Italy.; Department of Public Health and Pediatrics, University of Turin, Turin, Italy., Andreou D; Department of Orthopaedics and Trauma, Medical University of Graz, Graz, Austria., Baecklund F; Pediatric Oncology Unit, Karolinska University Hospital, Stockholm, Sweden., Baumhoer D; Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland., Bielack SS; Center for Pediatric, Adolescent and Women's Medicine, Klinikum Stuttgart-Olgahospital, Stuttgart Cancer Centre, Stuttgart, Germany., Botchu R; Department of Musculoskeletal Radiology, Royal Orthopaedic Hospital NHS Foundation Trust, Birmingham, United Kingdom., Boye K; Department of Oncology, Oslo University Hospital, Oslo, Norway., Brennan B; Paediatric Oncology, Royal Manchester Children's Hospital, Central Manchester University Hospital NHS Foundation Trust, Manchester, United Kingdom., Capra M; Haematology/Oncology, Children's Health Ireland at Crumlin, Dublin, Ireland., Cottone L; Department of Pathology, UCL Cancer Institute, University College London, London, United Kingdom., Dirksen U; Pediatrics III, West German Cancer Center, University Hospital Essen, German Cancer Consortium (DKTK) Site Essen, Cancer Research Center (NCT) Cologne-Essen, University of Duisburg-Essen, Essen, Germany., Fagioli F; Pediatric Oncology, Regina Margherita Children's Hospital, Turin, Italy.; Department of Public Health and Pediatrics, University of Turin, Turin, Italy., Fernandez N; Patient and Parent Advocacy Group, FOSTER, Washington, District of Columbia., Flanagan AM; Department of Pathology, UCL Cancer Institute, University College London, London, United Kingdom.; Histopathology, The Royal National Orthopaedic Hospital NHS Trust, Stanmore, United Kingdom., Gambarotti M; Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy., Gaspar N; Department of Oncology for Child and Adolescent, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.; U1015, Université Paris-Saclay, Villejuif, France., Gelderblom H; Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., Gerrand C; Orthopaedic Oncology, The Royal National Orthopaedic Hospital NHS Trust, Stanmore, United Kingdom., Gomez-Mascard A; Department of Pathology, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.; EQ ONCOSARC, CRCT Inserm/UT3, ERL CNRS, Toulouse, France., Hardes J; Tumour Orthopaedics, University Hospital Essen, German Cancer Consortium (DKTK) Site Essen, Cancer Research Center (NCT) Cologne-Essen, University of Duisburg-Essen, Essen, Germany., Hecker-Nolting S; Center for Pediatric, Adolescent and Women's Medicine, Klinikum Stuttgart-Olgahospital, Stuttgart Cancer Centre, Stuttgart, Germany., Kabickova E; Paediatric Haematology and Oncology, University Hospital Motol, Prague, Czech Republic., Kager L; Pediatrics, St Anna Children's Hospital, Medical University Vienna, Vienna, Austria.; St Anna Children's Cancer Research Institute, Vienna, Austria., Kanerva J; Hematology-Oncology and Stem Cell Transplantation, HUS Helsinki University Hospital, New Children's Hospital, Helsinki, Finland., Kester LA; Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands., Kuijjer ML; Computational Biology and Systems Medicine Group, Centre for Molecular Medicine Norway, University of Oslo, Oslo, Norway.; Pathology, Leiden University Medical Center, Leiden, the Netherlands.; Leiden Center for Computational Oncology, Leiden University Medical Center, Leiden, the Netherlands., Laurence V; Department of Medical Oncology, Institut Curie, Paris, France., Lervat C; Department of Pediatrics and AYA Oncology, Centre Oscar Lambret, Lille, France., Marchais A; Department of Oncology for Child and Adolescent, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France., Marec-Berard P; Institute of Hematology and Pediatric Oncology, Léon Bérard Center, Lyon, France., Mendes C; Portuguese Institute of Oncology of Lisbon, Lisbon, Portugal., Merks JHM; Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht, the Netherlands., Ory B; School of Medicine, Nantes Université, Nantes, France., Palmerini E; Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, IRCCS Istituto Orthopedico Rizzoli, Bologna, Italy., Pantziarka P; Patient and Parent Advocacy Group, FOSTER, Washington, District of Columbia.; Anticancer Fund, Meise, Belgium.; The George Pantziarka TP53 Trust, London, United Kingdom., Papakonstantinou E; Pediatric Hematology-Oncology, Ippokratio General Hospital of Thessaloniki, Thessaloniki, Greece., Piperno-Neumann S; Department of Pediatrics and AYA Oncology, Centre Oscar Lambret, Lille, France., Raciborska A; Oncology and Surgical Oncology for Children and Youth, Institute of Mother and Child, Warsaw, Poland., Roundhill EA; Children's Cancer Research Group, Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom., Rutkauskaite V; Center for Pediatric Oncology and Hematology, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania., Safwat A; The Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark., Scotlandi K; Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy., Staals EL; Orthopaedics and Trauma, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy., Strauss SJ; Department of Oncology, University College London Hospitals NHS Foundation Trust, UCL Cancer Institute, London, United Kingdom., Surdez D; Balgrist University Hospital, Faculty of Medicine, University of Zurich (UZH), Zurich, Switzerland., Sys GML; Department of Orthopaedic Surgery and Traumatology, Ghent University Hospital, Belgium., Tabone MD; Department of Hematology and Oncology, A. Trousseau Hospital, Sorbonne University, APHP, Paris, France., Toulmonde M; Department of Medical Oncology, Institut Bergonié, Bordeaux, France., Valverde C; Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain., van de Sande MAJ; Orthopaedic Oncology, Leiden University Medical Centre, Leiden, the Netherlands., Wörtler K; Musculoskeletal Radiology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany., Campbell-Hewson Q; Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom., McCabe MG; Division of Cancer Sciences, School of Medical Sciences, The University of Manchester, Manchester, United Kingdom.; The Christie NHS Foundation Trust, Manchester, United Kingdom., Nathrath M; Children's Cancer Research Center, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.; Pediatric Oncology, Klinikum Kassel, Kassel, Germany. |
| المصدر: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Aug 15; Vol. 30 (16), pp. 3395-3406. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Denville, NJ : American Association for Cancer Research, c1995- |
| مواضيع طبية MeSH: | Osteosarcoma*/therapy , Osteosarcoma*/pathology , Osteosarcoma*/diagnosis , Sarcoma, Ewing*/therapy , Sarcoma, Ewing*/pathology , Sarcoma, Ewing*/diagnosis , Bone Neoplasms*/therapy , Bone Neoplasms*/pathology , Specimen Handling*/methods , Specimen Handling*/standards, Humans ; Europe ; Biomarkers, Tumor ; Biological Specimen Banks |
| مستخلص: | Osteosarcoma and Ewing sarcoma are bone tumors mostly diagnosed in children, adolescents, and young adults. Despite multimodal therapy, morbidity is high and survival rates remain low, especially in the metastatic disease setting. Trials investigating targeted therapies and immunotherapies have not been groundbreaking. Better understanding of biological subgroups, the role of the tumor immune microenvironment, factors that promote metastasis, and clinical biomarkers of prognosis and drug response are required to make progress. A prerequisite to achieve desired success is a thorough, systematic, and clinically linked biological analysis of patient samples, but disease rarity and tissue processing challenges such as logistics and infrastructure have contributed to a lack of relevant samples for clinical care and research. There is a need for a Europe-wide framework to be implemented for the adequate and minimal sampling, processing, storage, and analysis of patient samples. Two international panels of scientists, clinicians, and patient and parent advocates have formed the Fight Osteosarcoma Through European Research consortium and the Euro Ewing Consortium. The consortia shared their expertise and institutional practices to formulate new guidelines. We report new reference standards for adequate and minimally required sampling (time points, diagnostic samples, and liquid biopsy tubes), handling, and biobanking to enable advanced biological studies in bone sarcoma. We describe standards for analysis and annotation to drive collaboration and data harmonization with practical, legal, and ethical considerations. This position paper provides comprehensive guidelines that should become the new standards of care that will accelerate scientific progress, promote collaboration, and improve outcomes. (©2024 The Authors; Published by the American Association for Cancer Research.) |
| References: | J Clin Oncol. 2010 Jul 10;28(20):3284-91. (PMID: 20547982) Pediatr Blood Cancer. 2014 Mar;61(3):452-6. (PMID: 23956055) Lancet Oncol. 2015 Sep;16(9):e425-e426. (PMID: 26370347) Cancer Cell. 2021 Jun 14;39(6):810-826.e9. (PMID: 33930311) Lancet. 2022 Oct 29;400(10362):1513-1521. (PMID: 36522207) Skeletal Radiol. 2006 Apr;35(4):195-201. (PMID: 16489465) Nat Commun. 2021 May 28;12(1):3230. (PMID: 34050156) Pediatr Blood Cancer. 2019 Feb;66(2):e27524. (PMID: 30378256) Cells. 2021 Feb 17;10(2):. (PMID: 33671173) J Clin Oncol. 2011 Dec 1;29(34):4534-40. (PMID: 22025154) J Clin Oncol. 2021 Dec 20;39(36):4029-4038. (PMID: 34652968) Lancet Oncol. 2020 Mar;21(3):446-455. (PMID: 32078813) Sci Rep. 2019 Aug 21;9(1):12174. (PMID: 31434953) PLoS One. 2009;4(3):e4932. (PMID: 19305498) Cancer. 2014 Aug 15;120(16):2448-56. (PMID: 24797726) Skeletal Radiol. 2005 Jun;34(6):307-13. (PMID: 15834722) Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10149-54. (PMID: 18626011) Histopathology. 2023 Mar;82(4):531-540. (PMID: 36464647) Ann Oncol. 2021 Dec;32(12):1520-1536. (PMID: 34500044) Cancer Cell. 2021 Jun 14;39(6):827-844.e10. (PMID: 34129824) Biol Proced Online. 2015 Jun 06;17:10. (PMID: 26109911) Ann Oncol. 2011 May;22(5):1228-1235. (PMID: 21030381) J Clin Oncol. 2015 Jul 10;33(20):2279-87. (PMID: 26033801) Skeletal Radiol. 2021 Feb;50(2):281-299. (PMID: 32815040) Cell Rep. 2014 Apr 10;7(1):104-12. (PMID: 24703847) Nat Commun. 2015 Dec 03;6:8940. (PMID: 26632267) J Clin Oncol. 2019 Dec 1;37(34):3192-3202. (PMID: 31553693) Oncogene. 2016 Jun 2;35(22):2852-61. (PMID: 26387545) Clin Cancer Res. 2024 Feb 16;30(4):849-864. (PMID: 37703185) Nat Rev Clin Oncol. 2021 Oct;18(10):609-624. (PMID: 34131316) Eur J Cancer. 2018 Jan;88:57-66. (PMID: 29190507) Cancer Res. 2023 Nov 15;83(22):3796-3812. (PMID: 37812025) J Bone Oncol. 2021 Oct 20;31:100398. (PMID: 35340569) Cancer. 2020 Jan 1;126(9):1917-1928. (PMID: 32022262) NPJ Precis Oncol. 2022 Sep 17;6(1):65. (PMID: 36115869) Nat Med. 2017 Mar;23(3):386-395. (PMID: 28134926) Pediatr Blood Cancer. 2016 Oct;63(10):1761-70. (PMID: 27362300) Ann Oncol. 2017 Nov 01;28(11):2852-2859. (PMID: 29117335) JCO Precis Oncol. 2023 Mar;7:e2200334. (PMID: 36996377) Rev Bras Ortop. 2015 Nov 04;47(5):631-7. (PMID: 27047877) Nature. 1992 Sep 10;359(6391):162-5. (PMID: 1522903) Cancer. 2022 May 15;128(10):1958-1966. (PMID: 35201621) J Clin Oncol. 2011 Dec 1;29(34):4541-7. (PMID: 22025149) Methods Mol Biol. 2021;2226:223-242. (PMID: 33326106) J Clin Oncol. 2012 May 20;30(15):1849-56. (PMID: 22508822) Radiology. 2008 Sep;248(3):962-70. (PMID: 18710986) ACS Biomater Sci Eng. 2020 Jan 13;6(1):539-552. (PMID: 33463239) J Clin Oncol. 2023 Apr 10;41(11):2098-2107. (PMID: 36669140) Br J Cancer. 2022 Dec;127(12):2220-2226. (PMID: 36221002) Cancer Res. 2022 Mar 15;82(6):974-985. (PMID: 35078815) Lancet Oncol. 2019 Jan;20(1):120-133. (PMID: 30477937) Cell Oncol (Dordr). 2021 Oct;44(5):1065-1085. (PMID: 34403115) J Clin Oncol. 2016 Sep 1;34(25):3031-8. (PMID: 27400942) Cancer Treat Rev. 2023 Nov;120:102625. (PMID: 37738712) J Clin Oncol. 2022 Jul 20;40(21):2307-2320. (PMID: 35427190) Nat Commun. 2024 Jan 2;15(1):180. (PMID: 38167338) Front Oncol. 2023 Jun 12;13:1166063. (PMID: 37377921) Cancer Treat Res Commun. 2021;27:100307. (PMID: 33453605) J Clin Oncol. 2020 Aug 1;38(22):2543-2551. (PMID: 32530760) Nat Rev Dis Primers. 2018 Jul 5;4(1):5. (PMID: 29977059) Oncotarget. 2016 Dec 27;7(52):86594-86607. (PMID: 27863409) Biomaterials. 2018 Jan;150:150-161. (PMID: 29040875) J Clin Oncol. 1992 Oct;10(10):1579-91. (PMID: 1403038) BMC Cancer. 2014 Mar 10;14:169. (PMID: 24612486) Cancer Med. 2021 Mar;10(5):1589-1604. (PMID: 33452711) J Clin Oncol. 2012 Nov 20;30(33):4148-54. (PMID: 23091096) Commun Biol. 2023 Sep 18;6(1):949. (PMID: 37723198) Med Pediatr Oncol. 1995 Jan;24(1):6-12. (PMID: 7968796) STAR Protoc. 2020 Sep 18;1(2):. (PMID: 33043307) AJR Am J Roentgenol. 2020 Sep;215(3):523-533. (PMID: 32755186) BMC Cancer. 2014 Nov 05;14:813. (PMID: 25374341) Radiographics. 2007 Jan-Feb;27(1):189-205; discussion 206. (PMID: 17235007) J Bone Oncol. 2023 Mar 05;39:100474. (PMID: 36936386) J Clin Oncol. 2015 Sep 20;33(27):3036-46. (PMID: 26304893) Clin Orthop Relat Res. 2017 Feb;475(2):511-518. (PMID: 27655183) Nature. 2012 Mar 28;483(7391):570-5. (PMID: 22460902) Eur J Cancer. 2013 Feb;49(3):684-95. (PMID: 23079473) Eur J Hum Genet. 2010 Jul;18(7):741-5. (PMID: 20332813) Oncogene. 2002 Jan 10;21(2):307-18. (PMID: 11803474) Cancer Discov. 2019 Jan;9(1):46-63. (PMID: 30266815) Oncogene. 2020 Aug;39(33):5553-5569. (PMID: 32655131) Proc Natl Acad Sci U S A. 2023 Sep 26;120(39):e2302101120. (PMID: 37729195) Ann Oncol. 2012 Feb;23(2):508-16. (PMID: 21527590) Diagn Interv Imaging. 2016 Mar;97(3):327-31. (PMID: 26616843) Lancet Oncol. 2016 Oct;17(10):1396-1408. (PMID: 27569442) Lancet. 1997 Sep 27;350(9082):911-7. (PMID: 9314869) Pathology. 2019 Jan;51(1):113-116. (PMID: 30497804) Sci Rep. 2017 Jul 10;7(1):4991. (PMID: 28694510) ESMO Open. 2021 Oct;6(5):100250. (PMID: 34562750) Cancer Med. 2023 Jan;12(2):1532-1539. (PMID: 35950293) Oncotarget. 2016 Apr 19;7(16):21298-314. (PMID: 26802029) Ann Oncol. 2019 Apr 1;30(4):582-588. (PMID: 30715153) Cancer Lett. 2019 Jul 1;453:142-157. (PMID: 30910588) Pediatr Blood Cancer. 2022 Dec;69(12):e29959. (PMID: 36106829) J Pathol. 2021 Aug;254(5):556-566. (PMID: 33963544) |
| معلومات مُعتمدة: | BCRT/8422 and BCRT/7721 Bone Cancer Research Trust (BCRT); Foerderkreis Krebskranke Kinder eV Stuttgart; DKS 2021.13 German Child Cancer Foundation |
| المشرفين على المادة: | 0 (Biomarkers, Tumor) |
| تواريخ الأحداث: | Date Created: 20240613 Date Completed: 20240815 Latest Revision: 20240822 |
| رمز التحديث: | 20240822 |
| مُعرف محوري في PubMed: | PMC11334773 |
| DOI: | 10.1158/1078-0432.CCR-24-0101 |
| PMID: | 38869831 |
| قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!